Gurung, Sthapit, and Rohit: Globe salvaging conservative management of Retinoblastoma


Introduction

Retinoblastoma is the most common intraocular tumor of children with prevalence of 1:20000 live births in the western world.1 But they contribute only a few percent to global burden due to tumors in the world; hence seeking less attention and budgeting.2 Developing countries lack both manpower and resources to handle the few but fatal tumors of the eye. Conservative management with focal and systemic therapy is popular in saving lives and eyes of retinoblastoma patients but costs are a big limiting factor for developing countries. Many centers still opt for surgical management; skills, cost and availability of focal and systemic therapy still being a limiting factor. The objective of our study was to describe the demography of the disease in Nepal and to evaluate the outcome of globe salvaging conservative management. We present a retrospective study of our retinoblastoma patients with globe salvaging conservative management wherever possible and their outcome.

Materials and Methods

It is a retrospective, non-comparative interventional study done at oculoplasty and ocular oncology department of Tilganga Institute of Ophthalmology (TIO), Kathmandu Nepal. All consecutive new retinoblastoma case records who presented in the year 2017-2018 were evaluated and treated by a single ocular oncologist (PRS) were included in the study. Patient's data were retrieved from our electronic medical record system and fundus photographs taken during serial examination under anesthesia (EUAs). The study has been approved by the institutional review board of TIO.

The suspected cases of Retinoblastoma were diagnosed clinically with examination under Anesthesia and fundus photography done wherever possible. Demographic data collected included age at presentation, sex, presenting symptoms, family history, geographic distribution and laterality. B scan and computed Tomography/MRI brain and orbit were done to rule out extra ocular, optic nerve and extra orbital extension. Patients were categorized into intraocular and orbital retinoblastoma. Intraocular tumors were grouped according to Intraocular Classification of Retinoblastoma (ICRB) grading (Shields) into group A to E.

Orbital retinoblastoma and those with optic nerve invasion (seen in MRI/CT scan) were given high dose neoadjuvant chemotherapy with vincristine, etoposide, and carboplatin (VEC) 12 cycles. It was followed by enucleation with an implant and then external beam radiotherapy (EBRT) to orbit. ICRB Group B to E cases was treated with standard dose chemotherapy VEC 6 cycle. Focal therapies like Trans pupillary thermotherapy (TTT), periocular chemotherapy (POC) and Cryotherapy (cryo) were done during EUA before each chemo cycle. However, group E patients without clinical high-risk factors were also given a choice of primary enucleation. After completion of treatment, all the patients were followed up three months for 1 year and six monthly for two years and then yearly. Any recurrence was documented and treatment started again. All the enucleated patients received custom made prosthesis free of cost for social rehabilitation.

The clinical data were analyzed with regard to the outcome of the above treatment modalities- number of lives saved, eye salvaged, visual rehabilitation and social rehabilitation with prosthetic eye.

Results

In the study period thirty-five new retinoblastoma cases visited the oculoplasty and ocular oncology department at Tilganga Institute of Ophthalmology. Male children were more than female children (male 24(68.5%)). Of the 35 patients, 10 patients (28.5%) had bilateral disease. Mean age at presentation was 31.8 months (median 24 months; range 1-84 months). Table 1. All the patients were of Asian race with 4 patients who came from foreign country. Rests were from various districts of Nepal.

Table 1

Patient demographics

Demographics

Patients, n=35(%)

Age, months

Mean (median, range)

31.80(24,1-84)

Race

Asian

35(100%)

Sex

Male

24(68.57)

Female

11(31.43)

Heredity (according to family history, genetic testing not done)

Familial

2(5.71)

Non-familial

33(94.29)

Laterality of retinoblastoma

Unilateral

25

Bilateral

10

Nationality

Nepal

31

Foreign country

4

After examination and necessary investigations, the patients were classified into intraocular and orbital retinoblastoma. Out of 45 eyes, 6 eyes (13.3%) were found to have orbital retinoblastoma. The remaining 39 eyes with intraocular disease were further classified according to ICRB grouping.

Among 35 patients, 31 patients received medical management with systemic chemotherapy with three drugs (Vincristine, Etoposide and Carboplatin) for a mean of 6.86 cycles (range 2 to 12 cycles). 12 cycles of High dose chemotherapy were given to 9 patients (29%), among them 6 patients had presented with orbital disease and 3 patients had high risk positive after enucleation. One patient who received 2 cycles as neoadjuvant chemotherapy was lost follow-up and came back after 5 months with phthisis bulbi and underwent enucleation surgery. Rest of the patients received 6 cycles of standard dose chemotherapy as shown in Table 2. Of the 10 patients who underwent Chemo reduction, 12 eyes also received focal therapies every month before next chemo cycle in the form of Trans pupillary thermotherapy (TTT in 8 eyes), periocular Topotecan injections in 4 and periocular Carboplatin in one patient.

Table 2

Globe salvaging conservative management of Retinoblastoma: Management (After excluding Lost to follow up)

Clinical characteristics

Eyes, n=35(%)

Management

Medical only

12(34.28)

Surgical only

4(11.43)

Medical and surgical

12(34.28)

Medical, surgical, EBRT

7(2)

Chemotherapy (VEC)

Eyes, n=31(%)

Neoadjuvant

15(48.39)

Chemo reduction

10(32.26)

Adjuvant chemo

6(19.35)

Standard chemotherapy

22(70.97)

High dose Chemotherapy

9(29.03)

Chemotherapy cycles

Mean (median, range)

6.86(6,2-12)

Enucleation

23

High risk factor positive

9

Periocular Topotecan

4 patients

Periocular Carboplatin

1 patient

Trans pupillary Thermotherapy

8 patients

Twenty-three eyes underwent surgical management with enucleation with implant. Among them only four had primary enucleation while the rest of them underwent secondary enucleation after neoadjuvant chemotherapy. Enucleated patients were rehabilitated with custom made prosthesis. At the end of the study period, we could salvage 12 eyes (26.66%). Life salvage was confirmed in 26 patients while 7 patients were lost to follow up after near completion of treatment as shown in Table 3.

Table 3

Globe salvaging conservative management of Retinoblastoma: Outcome (excluding lost to follow up)

Outcome

Eyes, n=35; patients, n=28

Duration of follow up from first visit (months)

Mean (median, range)

7.55(9,1-12)

Eyes salvage

12(34.29%)

Life salvage

26 patients (92.86%)

Expired

2 patients (7.14%)

Lost to follow up

7 patients

Figure 1

Group E Retinoblastoma with large tumor at macular associated with total bullous retinal detachment

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/fa444353-9604-43c3-99be-7ac63b4324d2image1.png
Figure 2

Fundus picture of same eye with regressed tumor leaving fibrous scar after conservative management

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/fa444353-9604-43c3-99be-7ac63b4324d2image2.png

Discussion

Recent studies have shown trends for earlier presentation of retinoblastoma patients, hence earlier detection of tumor and opportunity for conservative globe preserving treatments. Retinoblastoma diagnosis and treatment is an example of advances made in medicine where a near lethal pediatric cancer with around 5% survival rate in 19th century has turned to a curable disease with highest survival rate among pediatric cancers.

Retinoblastoma is the most common primary cancer of the eye in children. It attracts less attention in global policy making because it represents only approximately 4% of childhood cancer and less than 1% of all human cancers.3 Developed countries have achieved near zero mortality while developing countries like Nepal still sees high mortality (19%) and morbidity in retinoblastoma patients.4

In our study male patients were double the number of female patients similar to Congo.5 Though most studies show male preponderance of disease, studies in Singapore, Iran and New South Wales show female preponderance.6, 7, 8 The mean age of presentation in our study (31.8 months) was consistent with most studies in Asian and African countries but was higher than USA and New South Wales.8 Different studies in Nepal show gradual increase in number of cases per year with earlier presentations. In our study, we saw 35 cases during one year of our study period which is the highest number of patients per year among all studies done in Nepal. This probably reflects increased public awareness, easy access to health care services and inclusion of ocular oncologist clinics in our center. More than 71% of our patients had unilateral disease and are consistent with different studies with 57 to 85% unilateral cases.4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 Leukocoria is the earliest presentation and was most common symptom and sign in our patient like different studies in brazil, Egypt ,Singapore, Congo, Iran, New York, Mongolia, China, New South Wales and Foreign country, while proptosis was the most commonest in Indonesia, Nigeria, Africa and a study in eastern Nepal.7, 13, 18, 19 The earlier research on retinoblastoma in Nepal shows leukocoria as the commonest mode of presentation10, 17 while one study shows proptosis as the most common presentation.19 Surgery was the most favored mode of management and enucleation (90%; 78.38%; 55.81%) was the most common mode of treatment followed by exenteration (6.7%; 5.40%; 41.86%).10, 17, 19 All enucleated patients were rehabilitated with custom made prosthesis (CMP). CMP is better than stock prosthesis and gives better cosmetic rehabilitation.20, 21 Ben et al in their study reported retinoblastoma as the most common cause of exenteration.22 None of our Rb patients underwent exenteration in a given study period. We could save 26 patients (92.86%) during our study period; it is encouraging though not in par with the developed countries like Singapore with 91%, Europe with 95% and USA with 96% survival rate.6 Our figure may be biased since we did not take the 7 lost to follow patients into account. Presuming the lost to follow up patient died, our survival rate will be 74.3%. Republic of Congo study show over 75% lost to follow up with presumed mortality of 92.5%.5 We salvaged 34.29% of eyes most of them were group B, C and D; It is less in comparison to Singapore with 100% glove preservation in Group A, B, C and 23.1%in group D and South Korea they salvaged 66.7% in group c and 26.7% in group D. This may be due to more advanced cases (57.78%) of our patients were in group E. 6 Neoadjuvant chemotherapy was able to prevent orbital Exenteration, in a prospective study by Radhakrishnan et al. 23 In our study 15 cases (48.39%) were given neoadjuvant chemo, chemo reduction was done in 10 cases (32.26%) and adjuvant chemo was given in 6 cases (19.35%). Four patients received periocular topotecan and one patient received periocular carboplatin, Periocular topotecan has been known to be effective against focal vitreous seeds along with intravenous chemotherapy.24

In a large scale retrospective study in Foreign country, patients were treated with systemic chemotherapy (60%) followed by enucleation (35%) and they stated a survival rate of 89% in 10 years with 8% death in 44 month follow up.16 Shah et al found a mortality rate of 19% in their study with patients undergoing chemotherapy though the cause of death was not analyzed. They presented a 10 year survival rate of 23.8% among their 42 cases.4 Badu et al study showed 44.19% mortality among their patients.19 In our study chemotherapy and EBRT were done in different centers with respective subspecialty facilities. Hence the cause of death couldn’t be classified to disease progression or adverse effect of treatment. Two patients (7.14%) died during chemotherapy; 26 patients (92.86%) survived the 1-year study period. Interestingly 12(34.29%) eyes were salvaged in our study. Till date we do not have molecular testing for Rb in Nepal and effective genetic counseling is difficult to deliver for informed family planning decisions though Ram Prasad, V.L. et al has aptly described its importance in familial Rb.25 Retinoblastoma programs like in Central America may decrease defaulters and increase survival rates in Nepal.26

In most previous studies, conservative management including focal therapy was not popular. Exenteration is rarely done but enucleation is still practiced widely due to relatively ease, cost friendly and one-time procedure for advanced cases. In our study increased awareness (via patients, social media and newspaper) has increased the patient flow and decreased median age of presentation. Addition of Trans pupillary thermotherapy, portable fundus camera, examination under anesthesia (EUA), separate ocular oncology clinics has facilitated intraocular and periocular chemotherapy and hence promoted safe conservative management of retinoblastoma. Conservative management of retinoblastoma is facilitated by patient awareness, early presentation and availability of equipment and trained human resources. Dedicated oncology department, increase in trained manpower, public awareness and availability of multimodality treatment has decreased mortality due to retinoblastoma but early diagnosis, compliance with treatment and follow up is still an issue to be concerned.

Conclusion

Conservative glove salvaging management has good result in early retinoblastoma cases. Early initiation of neoadjuvant high dose chemotherapy can avoid mutilating surgery like exenteration even in orbital retinoblastoma.

Conflicts of Interest

All contributing authors declare no conflicts of interest.

Source of Funding

None.

References

1 

CL Shields JA Shields Basic understanding of current classification and management of retinoblastomaCurr Opin Ophthalmol20061732283410.1097/01.icu.0000193079.55240.18

2 

RL Siegel KD Miller A Jemal Cancer statisticsCA Cancer J Clin201969173410.3322/caac.21551

3 

DH Abramson Retinoblastoma in the 20th Century: Past Success and Future Challenges The Weisenfeld LectureInvest Opthalmology Visual Sci200546826849110.1167/iovs.04-1462

4 

S K Prasad S Rohit R Pankaj K Sonali Retinoblastoma: Ten Years Experience at Kanti Children's HospitalJ Nepal Med Assoc20135219210.31729/jnma.2429

5 

AK Lukusa MN Aloni B Kadima-Tshimanga M Mvitu-Muaka J L Gini Ehungu R Ngiyulu Retinoblastoma in the Democratic Republic of Congo: 20-Year Review from a Tertiary Hospital in KinshasaJ Cancer Epidemiol201210.1155/2012/920468

6 

FP Miao Lim SY Soh JV Iyer AM Tan H Swati BL Quah Clinical Profile, Management, and Outcome of Retinoblastoma in SingaporeJ Pediatr Ophthalmol Strabismus20135021061210.3928/01913913-20121211-01

7 

GA Miranda GWS Simanjuntak Clinical Findings and Demography of Retinoblastoma in a Tertiary Hospital in a Remote Area in a Developing CountryAsian Pacific J Cancer Care20183210.31557/APJCC.2018.3.2.37

8 

D Azar C Donaldson F Kalapesi R Cumming Retinoblastoma in New South WalesJ Pediatr Hematol/Oncol197528106426

9 

H El Zomor R Nour A Alieldin H Taha M M Montasr E Moussa Clinical presentation of intraocular retinoblastoma; 5-year hospital-based registry in EgyptJ Egypt National Cancer Inst201527419520310.1016/j.jnci.2015.09.002

10 

R Saiju G Moore U Shrestha MK Shrestha S Ruit Retinoblastoma: geographic distribution and presentation at a tertiary eye care centre in Kathmandu, NepalNepalese J Ophthalmol2013521697610.3126/nepjoph.v5i2.8708

11 

E Broaddus A Topham A D Singh Survival with retinoblastoma in the USA: 1975-2004Br J Ophthalmol200993124710.1136/bjo.2008.143842

12 

S Kaliki V Srinivasan A Gupta DK Mishra MN Naik Clinical Features Predictive of High-Risk Retinoblastoma in 403 Asian Indian PatientsOphthalmol2015122611657210.1016/j.ophtha.2015.01.018

13 

J F Owoeye E A Afolayan D S Ademola-Popoola Retinoblastoma--a clinico-pathological study in Ilorin, NigeriaAfr J Health Sci2006131-211723

14 

T Chuluunbat B Jamiyanjav B Munkhuu U Bazarsad A Molom LY Kao Retinoblastoma in Mongolia: Clinical characteristics and survival from 1987 to 2014Taiwan J Ophthalmol201662798410.1016/j.tjo.2016.04.004

15 

J Zhao S Li J Shi N Wang Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in ChinaB J Ophthalmol201195101372510.1136/bjo.2010.191130

16 

S Kaliki A Patel S Iram G Ramappa A Mohamed VAR Palkonda Retinoblastoma In India: Clinical Presentation and Outcome in 1,457 Patients (2,074 Eyes)Retina201939237991

17 

HB Gurung B Limbu AJ Lama H Brown R Saiju Retinoblastoma: changing trend in a tertiary eye centreIndian J Clin Exp Ophthalmol2019522526

18 

R.J.C. Bowman M. Mafwiri P. Luthert J. Luande M. Wood Outcome of retinoblastoma in east AfricaPediatr Blood Cancer2008501160210.1002/pbc.21080

19 

B Badhu S P Sah SKD Thakur S Dulal S Kumar A Sood Clinical presentation of retinoblastoma in Eastern NepalClin Exp Ophthalmol2005334386910.1111/j.1442-9071.2005.01010.x

20 

T Sethi H Harianawala C Haylock M Kheur Fabrication of a custom ocular prosthesisMiddle East Afr J Ophthalmol2014213271410.4103/0974-9233.134694

21 

R Gunaseelaraj S Karthikeyan MN Kumar T Balamurugan AR Jagadeeshwaran Custom-made ocular prosthesisJ Pharm Bioallied Sci201246177910.4103/0975-7406.100264

22 

L Ben M Aemero AG Gushchin GH Moore S Rohit Clinico-Pathological Patterns of Patients Who Underwent Orbital Exenteration in a Tertiary Eye Hospital of NepalEthiop J Health Sci2016266543810.4314/ejhs.v26i6.6

23 

V Radhakrishnan S Kashyap N Pushker S Sharma S Pathy BK Mohanti Outcome, Pathologic Findings, and Compliance in Orbital Retinoblastoma (International Retinoblastoma Staging System Stage III) Treated with Neoadjuvant ChemotherapyOphthalmol201211971470710.1016/j.ophtha.2012.01.029

24 

SG Honavar PR Sthapit R Rao Periocular topotecan for vitreous seeds in retinoblastomaIndian J Ophthalmol201866121833810.4103/ijo.ijo_737_18

25 

V L Ramprasad J Madhavan S Murugan J Sujatha S Suresh T Sharma Retinoblastoma in India : microsatellite analysis and its application in genetic counselingMol Diagn Ther20071116370

26 

JA Wilimas MW Wilson BG Haik M Barnoya L Fu M Castellanos Development of retinoblastoma programs in Central AmericaPediatr Blood Cancer200953142610.1002/pbc.21984



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution License Attribution 4.0 International (CC BY 4.0). which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


  • Article highlights
  • Article tables
  • Article images

Article History

Received : 20-02-2021

Accepted : 16-03-2021

Available online : 28-04-2021


View Article

PDF File   Full Text Article


Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijooo.2021.006


Article Metrics






Article Access statistics

Viewed: 178

PDF Downloaded: 101